Don Reisinger

Stay informed with Don Reisinger’s coverage and analysis for Coins2Day.

Page 11 of 100

  • Time Magazine Honors Influential People With Its Time 100 EventTech

    Apple CEO Tim Cook Speaks Out About Doing ‘What’s Right’ Despite the Backlash

    By
  • Tesla CEO Elon Musk leaves Manhattan federal court after a hearing on his fraud settlement with the SEC in New YorkTech

    3 Takeaways From Tesla’s Autonomy Day Event

    By
  • Mobile App IllustrationsTech

    Why This Year’s New iPhones Won’t Have 5G

    By
  • In this photo illustration a Qualcomm logo seen displayed onTech

    Qualcomm Cease Fire Tops Big Week in Apple News

    By
  • US-IT-INTERNET-COMPUTERS-TELECOM-APPLETech

    Listen Up: Apple’s AirPods Face Growing List of Challengers

    By
  • Samsung Hosts Annual Galaxy Unpacked Event Unveiling New Devices Including S10 SmartphoneTech

    Samsung Galaxy Fold: Your Guide to the $2,000 Smartphone

    By
  • Annual Allen And Co. Investors Meeting Draws CEO's And Business Leaders To Sun Valley, IdahoTech

    Disney Plus Makes Bob Iger’s Apple Board Seat an Awkward Fit

    By
  • TOPSHOT-DOUNIAMAG-US-SPACE-AEROSPACE-SPACEXTech

    3 Reasons Why the Second Falcon Heavy Launch Is a Make-or-Break Moment for SpaceX

    By
  • Apple's New HomePod Now Available Within Its StoresTech

    HomePod Is Still Too Expensive—and It’s Crushing Apple’s Smart Home Push

    By
  • Game Stop store in New York CityTech

    Is GameStop Played Out?

    By
  • Donald Reisinger-FacebookTech

    I Thought I Understood Facebook. Then My Dad Died

    By
  • Popular Social Media LogosTech

    Apple Hopes Price Cuts Will Reverse Slide in China. But Are They Enough?

    By
  • US-IT-APPLE-LIFESTYLE-COMPUTERSTech

    Apple Card vs. American Express Platinum: A High-End Credit Card Face-Off

    By
  • Apple's Schiller speaks during a launch event in CupertinoTech

    Apple’s Now-Canceled AirPower Charging Mat Is Just One in a Series of Hardware Gaffes. Here Are Four More

    By
  • AstraZeneca - Factory

    AstraZeneca Will Pay Up to $6.9 Billion for Rights to Japanese Drugmaker’s Cancer Drug

    By